Learn more about Peter Attia’s digital program
Why a recent study hasn’t shaken my faith in statins
A rebuttal of Byrne et al.
Low LDL cholesterol and neural development
Why LDL-lowering treatments don’t pit head against heart
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
Does fish oil cause cardiac arrhythmia in high-risk individuals?
Reports of increased risk of atrial fibrillation in high-risk patients taking fish oil
Does low cholesterol cause cognitive impairment? Part II
Safety of lipid-lowering therapy
Does low cholesterol cause cognitive impairment? Part I
Safety of lipid-lowering therapy
Are continuous glucose monitors a waste of time for people without diabetes?
Some experts suggest CGMs are useless for nondiabetics. I disagree.
Early risk assessment markers to delay cardiovascular disease
Identifying risk decades before disease manifests
#134 – James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise
“If exercise were a drug, it would be the best drug we have for preventing heart disease . . .. But like with any drug, you’ve got to get the dose right.” — James O’Keefe
#132 – AMA #16: Exploring hot and cold therapy
“All of the work that went into this analysis earlier in the year, it really changed my tune. And I think I’m now at the point where I kind of want to have a sauna, frankly, in the tool kit for longevity.” — Peter Attia